drugset / Trial / NCT00661479

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

NCT00661479

Phase 1/2 Completed 21 enrolled Allergan
Non-randomizedSingle-groupSingle-blindTreatment

Summary

This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.

Timeline

Start
2008-07
Primary completion
2009-12
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 100 ug Intravitreal
Subject Brimonidine Small molecule 200 ug Intravitreal
Subject Brimonidine Small molecule 400 ug Intravitreal

Indications